Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...